99tcm-tetrofosmin scintimammography for detecting breast cancer: A comparative study with 99tcm-mibi

Nuclear Medicine Communications

Volumn 22, Issue 7, 2001, Pages 807-811

  Horne, T ^a   Pappo, I ^a   Cohen Pour, M ^a   Baumer, M ^b   Orda, R ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

99Tcm sestamibi; Breast cancer; Scintimammography

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; DIAGNOSTIC AGENT; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST LESION; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMAGE ANALYSIS; RADIODIAGNOSIS; SCINTIMAMMOGRAPHY; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; MAMMOGRAPHY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0034743527     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200107000-00012     Document Type: Review

References (27)

1. Garne JP, Aspergen K, Balldin G, Ranstam J. Increasing incidence of and declining mortality from breast cancer: trends in Malmo, Sweden, 1961-1992. Cancer 1997; 79: 69-74.
2. Sondlik EJ. Breast cancer trends: incidence, mortality and survival. Cancer 1994; 74: 995-999.
3. Lopez MJ, Blackwell CW. Breast cancer detected by screening: the importance of long-term follow-up. Surgery 1989; 106: 590-595.
4. Jackson VP, Hendrick RE, Feig SA, Kopans DB. Imaging of the radiographically dense breasts. Radiology 1993; 188: 297-301.
5. Bird RE, Wallace TW, Yankaskas BC. Analysis of cancer missed at screening mammography. Radiology 1992; 184: 613-617.
6. Khalkhali I, Cutrone JA, Diggles L, Mishkin FM. The role of nuclear imaging for the evaluation of patients with breast abnormalities. Nuclear Medicine Annual. Philadelphia: Lippincott-Raven, 1996: 113-142.
7. Khalkhali I, Cutrone JA, Mena IG et al. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196: 421-426.
8. Horne T, Pappo I, Orda R. The use of technetium-99m-sestamibi scintimammography (MIBI) for the detection of breast malignancies: the contribution of the count ratio for increasing the specificity. Nucl Med Commun 1999; 20: 511-516.
9. Palmedo H, Biersack HJ, Lastoria S et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med 1998; 25: 375-385.
10. Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.
11. Ciarmiello A, Del-Vecchio S, Silvestro P et al. Tumor clearance of technetium-99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998; 16: 1677-1683.
12. Maini CL, Tofani A, Sciuto R et al. Technetium-99m-MIBI scintigraphy in the assessment of neo-adjuvant chemotherapy in breast carcinoma. J Nucl Med 1997; 38: 1546-1551.
13. Higely B, Smith FW, Smith T et al. Technetium-99m-1,2-bis (2-ethoxyethyl) phosphoinoethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34: 30-38.
14. Jones S, Hendel RC. Technetium 99m tetrofosmin: a new myocardial perfusion agent. J Nucl Med Technol 1993; 21: 191-195.
15. Ballinger JR, Banneman J, Boxen I et al. Accumulation of Tc-99m tetrofosmin in breast tumor cells in-vitro: role of multidrug-resistance p-glycoprotein. J Nucl Med 1995; 36: 202p.
16. Rambaldi PF, Mansi L, Procaccini E, Di Gregorio F, Del vecchio E. Breast cancer detection with Tc-99m tetrofosmin. Clin Nucl Med 1995; 20: 703-705.
17. Madriaga P, Almoguera I, Alonso A et al. Technetium-99m tetrofosmin scintigraphy to evaluate breast lesions. Anticancer Res 1997; 17: 1619-1621.
18. Schillaci O, Scopinaro F, Danieli R et al. Scintimammography with technetium-99m tetrofosmin in suspected breast cancer. Anticancer Res 1997; 17: 1623-1626.
19. 99mTc-tetrofosmin scintimammography related to surgery. Eur J Surg Oncol 1999; 25: 152-156.
20. Mansi L, Rambaldi PF, Procaccini E et al. Scintimammography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases. Eur J Nucl Med 1996; 23: 932-939.
21. Ackay MN, Akin Y, Ozean O, Oren D. Tc-99m tetrofosmin in breast carcinoma and axillary lymph node metastases: a comparative study with Tc-99m MIBI. Clin Nucl Med 1997; 22: 832-834.
22. Berghammer P, Obwegeser R, Mulauer-Ertl S et al. 99m-Tc-tetrofosmin scintigraphy and breast cancer. Gynecol Oncol 1999; 73: 87-90.
23. Pappo I, Horne T, Orda R. Tc-99m-sestamibi scintimammography for the diagnosis of breast malignancies. Breast J 1998; 4: 441-446.
24. Fenlon HM, Phelan NC, Tierney S et al. Tc-99m tetrofosmin scintimammography as an adjunct to plain film mammography in palpable breast lesions. Clin Radiol 1998; 53: 17-24.
25. Obwegeser R, Berghammer P, Rodrigues M et al. A head to head comparison between technetium-99m-tetrofosmin and technetium-99m-MIBI scintigraphy to evaluate suspicious breast lesions. Eur J Nucl Med 1999; 26: 1553-1559.
26. Fenlon HM, Phelan NC, O’Sullivan P, Tierney S, Gorey T, Ennis JT. Benign versus malignant breast disease: comparison of contrast-enhanced MR imaging and Tc-99m tetrofosmin scintimammography. Radiology 1997; 205: 214-220.
27. 99Tc sestamibi scintimammography and trans-scan in diagnosing breast cancer. J Nucl Med 1999; 40: 376-380.